Sovateltide in cerebral ischaemic stroke: a profile of its use

Sovateltide (Tyvalzi^TM), a first-in-class selective endothelin B receptor agonist, is a valuable new therapy for the treatment of cerebral ischaemic stroke. It promotes neurovascular remodelling, increases cerebral blood flow, has anti-apoptotic activity, protects neural mitochondria, and enhances mitochondrial biogenesis. In a randomized, placebo-controlled phase 3 study in patients with cerebral ischaemic stroke, the addition of sovateltide within 24 h of symptom onset to standard of care treatment provided statistically significant and clinically meaningful improvement in neurological outcomes 90 days post-randomization. Additionally, sovateltide was generally well tolerated.